InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（1 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the full record of transactions filed by Newman Michael James, Directeur. Officer active across 1 company, notably Indaptus Therapeutics, Inc.. Aggregated, 2 filings have been logged. Split: 0 buy · 1 sell. Total volume traded: €26k. Activity tracked since 31 January 2022. The latest transaction was disclosed on 22 December 2025 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Newman Michael James
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报2 总计
52,204 股@ US$2.0377.5% 占其流量Common StockSEC:0001493152-25-029354:0
5,870 股@ US$5.000122.5% 占其流量Common StockSEC:0001493152-22-003002:0
2 条申报中的 2 条
About Newman Michael James
Michael James Newman serves as a Director and Chief Strategy Officer at Indaptus Therapeutics, Inc. He is responsible for formulating and executing the company's strategy, contributing to the organization's direction and growth. Michael plays a key role in developing innovative therapeutic solutions and leading strategic initiatives.
